Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study

奥曲肽 医学 倾向得分匹配 内科学 神经内分泌肿瘤 辅助治疗 胃肠病学 子群分析 回顾性队列研究 肿瘤科 癌症 生长抑素 置信区间
作者
Shiwei Guo,Heshui Wu,Suizhi Gao,Weiyu Hu,Hui Jiang,Yun Bian,Yijie Zhang,Bo Li,Gang� Li,Xuefeng Xu,Min Wang,Chenglin Zhu,Linlin Qu,Qiang Huang,Renyi Qin,Wenhui Lou,Gang Jin
出处
期刊:Journal of Neuroendocrinology [Wiley]
卷期号:36 (12): e13442-e13442 被引量:6
标识
DOI:10.1111/jne.13442
摘要

Adjuvant therapy for pancreatic neuroendocrine tumors (PanNETs) after radical resection lacks evidence-based data and remains controversial. This study aimed to validate whether long-acting octreotide is a potential candidate for adjuvant therapy in patients with G2 PanNETs at high recurrence risk by clustering real-world data. A retrospective review of patients with nonmetastatic grade 2 PanNETs who underwent radical resection at six research centers between 2008 and 2020 was conducted. Propensity score matching and inverse probability of treatment weight analysis were used to control confounding factors. Overall, 357 patients (octreotide group, n = 82; control group, n = 275) were analyzed. Kaplan-Meier survival analyses showed that the octreotide group had longer disease-free survival (DFS) compared with the control group (36 months: 93.3% vs. 79.0%, p = .0124; 60 months: 71% vs. 67.6%, p = .0596, respectively), as well as overall survival (OS) (60 months: 98% vs. 83.8%, p = .0117, respectively). Multivariate analyses indicated that octreotide long-acting repeatable (LAR) adjuvant therapy was associated with higher OS (p = .0270) at 60 months. Propensity score matching analysis showed that octreotide adjuvant therapy was associated with higher DFS (p = .0455) and OS (p = .0190) at 60 months. Similar results were obtained via inverse probability of treatment weight analysis. Subgroup analysis indicated that octreotide LAR was associated with a high DFS in patients with lymph node metastasis or Ki-67 <10% PanNETs. Adjuvant therapy with long-acting octreotide following radical resection of nonmetastatic G2 PanNETs may be associated with improved DFS and OS in a real-world setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
乐乐完成签到,获得积分20
刚刚
linus发布了新的文献求助10
刚刚
Gc完成签到,获得积分10
刚刚
LL完成签到,获得积分10
刚刚
研究牛牛完成签到,获得积分10
刚刚
柒玉染发布了新的文献求助10
1秒前
小陈发布了新的文献求助10
1秒前
傅三毒发布了新的文献求助10
1秒前
张丽彤发布了新的文献求助10
1秒前
美满的擎宇完成签到 ,获得积分10
1秒前
cL发布了新的文献求助10
1秒前
慕青的应助被迅速又晴采纳,获得10
1秒前
2秒前
客官们帮帮忙完成签到,获得积分10
2秒前
小郭发布了新的文献求助10
2秒前
科研通AI2S的应助被南玖采纳,获得30
2秒前
yanni完成签到,获得积分10
2秒前
大里完成签到 ,获得积分10
2秒前
木风落完成签到,获得积分10
2秒前
周Joyce发布了新的文献求助30
3秒前
饱满老鼠发布了新的文献求助10
3秒前
乐乐发布了新的文献求助30
3秒前
3秒前
4秒前
4秒前
wen完成签到 ,获得积分10
4秒前
奶油兔子发布了新的文献求助10
4秒前
4秒前
XulongGuan发布了新的文献求助10
4秒前
5秒前
5秒前
Wenlia的应助被甜甜的悲采纳,获得10
5秒前
ubless607举报方法的求助涉嫌违规
5秒前
linus完成签到,获得积分10
6秒前
冷酷的狗发布了新的文献求助10
6秒前
魅雪霓完成签到,获得积分10
6秒前
springlrt的应助被科研通管家采纳,获得20
6秒前
h11的应助被科研通管家采纳,获得10
6秒前
lingfeng完成签到 ,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174476
求助须知:如何正确求助?哪些是违规求助? 9566504
关于积分的说明 21786755
捐赠科研通 7768724
什么是DOI,文献DOI怎么找? 3431727
关于科研通互助平台的介绍 2555945
邀请新用户注册赠送积分活动 2477065